61 citations
,
January 2013 in “International Journal of Biological Macromolecules” Combining DHT and EDC improves the strength and stability of PADM scaffolds for tissue engineering.
7 citations
,
April 2025 in “Science Advances” Silicate-based therapy may help treat inflammatory heart disease by reducing immune inflammation.
2 citations
,
June 2023 in “Clinical Cosmetic and Investigational Dermatology” Using a dexpanthenol ointment after micro-needling speeds up skin healing without affecting benefits.
86 citations
,
July 1990 in “British Journal of Pharmacology” Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
18 citations
,
January 1990 in “Journal of The American Academy of Dermatology” Lower doses of dexamethasone can safely reduce high DHEAS levels in women with androgenic disorders.
1 citations
,
September 2016 in “Acta Chromatographica” Created method to measure doxazosin mesylate and finasteride together.
May 2024 in “Reactions weekly”
24 citations
,
May 1982 in “Biochemical Pharmacology” These drugs cause hair growth without affecting testosterone or adrenal hormones.
16 citations
,
April 2006 in “Pediatrics International” High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
6 citations
,
July 2016 in “Doklady Biochemistry and Biophysics” GD-23 reduces anxiety by relying on neurosteroid production.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
March 2023 in “Reactions Weekly”
9 citations
,
March 2024 in “Journal of Biomaterials Applications” Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
48 citations
,
June 2000 in “Japanese Journal of Cancer Research” Dimethylarsinic acid speeds up skin tumor growth in certain mice.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
9 citations
,
April 2006 in “International Journal of Dermatology” DFMO may help control hair growth and treat cancer.
January 2012 in “Chinese Clinical Oncology” Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
The treatment was not recommended due to limited effectiveness and significant side effects.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
7 citations
,
August 2021 in “Pharmaceutics” Freeze-dried dexamethasone nanoparticles in a hydrogel are stable and effective for treating alopecia areata.
January 2026 in “Food Science and Human Wellness” Krill oil may help reduce prostate enlargement and growth.
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
9 citations
,
May 2014 in “Clinical Cosmetic and Investigational Dermatology” Using tazarotene with GliSODin improves facial skin more than tazarotene alone.
14 citations
,
June 1982 in “Archives of Dermatology” A man had bad reactions to a hair loss treatment called DNCB.